X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells $10,016.10 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) COO Mary Dibiase sold 22,258 shares of the firm's stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $10,016.10. Following the completion of the transaction, the chief operating officer now directly owns 490,980 shares in the company, valued at approximately $220,941. This represents a 4.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $0.49 on Tuesday. X4 Pharmaceuticals, Inc. has a 52 week low of $0.26 and a 52 week high of $1.60. The firm has a market capitalization of $83.84 million, a P/E ratio of -5.46 and a beta of 0.14. The company has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.61. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Analysts Set New Price Targets

Several equities analysts have weighed in on XFOR shares. HC Wainwright reaffirmed a "buy" rating and set a $1.50 price target on shares of X4 Pharmaceuticals in a report on Tuesday, January 14th. Stifel Nicolaus decreased their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th.




Check Out Our Latest Stock Report on X4 Pharmaceuticals

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its stake in shares of X4 Pharmaceuticals by 233.0% in the 4th quarter. SG Americas Securities LLC now owns 183,152 shares of the company's stock valued at $134,000 after purchasing an additional 128,148 shares during the last quarter. Barclays PLC lifted its position in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company's stock worth $185,000 after buying an additional 183,861 shares during the last quarter. XTX Topco Ltd boosted its stake in X4 Pharmaceuticals by 41.7% during the third quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after buying an additional 46,397 shares during the period. Jane Street Group LLC increased its position in X4 Pharmaceuticals by 103.4% during the third quarter. Jane Street Group LLC now owns 248,447 shares of the company's stock valued at $166,000 after acquiring an additional 126,296 shares during the last quarter. Finally, State Street Corp raised its stake in shares of X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company's stock valued at $1,976,000 after acquiring an additional 189,105 shares during the period. Institutional investors own 72.03% of the company's stock.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

Featured Articles

Insider Buying and Selling by Quarter for X4 Pharmaceuticals (NASDAQ:XFOR)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.

Insider Buying or Selling at X4 Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for X4 Pharmaceuticals and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles